Is Myrtol® Standardized a New Alternative toward Antibiotics?
1, 1
- 1Department of Pulmonary Diseases, Klinikum Kassel, University Hospital of Southampton, Mönchebergstrasse 41‑43, D‑35125 Kassel, GERMANY.
CORRESPONDENCE
Maria Paparoupa
Department of Pulmonary Diseases, Klinikum Kassel University Hospital of Southampton, Mönchebergstrasse 41‑43, D‑35125 Kassel, GERMANY.
Volume 10, Issue 20 · pp. 143-146 · 2016 · DOI: 10.4103/0973-7847.194045
ABSTRACT
GeloMyrtol® and GeloMyrtol® forte, also known as Myrtol® standardized, is an herbal medical product (phytomedicine) obtained by a multistep distillation procedure from essential oils. The major biological marker of in vivo and ex vivo activity of Myrtol® standardized is the monoterpenes, d‑limonene, 1,8‑cineole, and alpha‑pinene. Myrtol® standardized is estimated to have antioxidative, anti‑inflammatory, and antibacterial potential while many studies confirmed its secretolytic and bronchospasmolytic effects. As such, the medication is proposed to be initiated in several acute and chronic infections of the upper and lower airway system as acute and chronic rhinosinusitis, acute and chronic bronchitis, and chronic obstructive pulmonary disease. This review intends to give an insight into several prescription indications of Myrtol® standardized, all involved mechanisms, and potential advantages toward antibiotic therapy, especially in cases when bacterial infection is uncertain.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Paparoupa, M., & Gillissen, A. (2016). Is Myrtol® Standardized a New Alternative toward Antibiotics?. Pharmacognosy Reviews, 10(20), 143-146. https://doi.org/10.4103/0973-7847.194045
Copyright and licence
© 2016 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which allows others to share and adapt the work for any purpose, as long as the original authors and source are credited. CC BY 4.0